mRNA drug developer Moderna and Merck have a personalized cancer therapy called intismeran, and it just hit its goals in a Phase III trial. After 1,137 patients with high-risk melanoma had surgery, those who got intismeran plus Keytruda saw significantly better outcomes on two key measures — recurrence and distant metastasis — than those who got Keytruda alone. Full efficacy data hasn't been released yet.
Here's what makes this drug different: every patient gets a different one. Doctors first sequence a patient's tumor and blood to find mutations unique to their cancer cells. Moderna then runs those mutations through a suite of AI algorithms to predict up to 34 neoantigens — cell-surface targets most likely to trigger an immune response, essentially targets the immune system can be trained to attack.
Once the targets are selected, Moderna encodes them into a piece of mRNA manufactured specifically for that patient. Injected into the body, that mRNA instructs cells to produce those cancer signatures, training the immune system to recognize and attack cancer cells carrying the same traits. Different tumor mutations, different AI-selected targets, different final mRNA product.
Cancer drugs used to work the old way: build one drug, then find the right group of patients. Intismeran flips that script. It starts by reading a single person's cancer, turning the tumor into sequencing data, calculating targets, and then encoding the result back into a drug. The Phase III win proves this one-drug-per-patient pipeline can actually scale to a large clinical trial.